Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu(Central South University), Quan Cheng(Central South University), Zhenjie Yi(Central South University), Haoyang Mo(Central South University), Peng Luo(Zhujiang Hospital), Luzhe Yan(Central South University), Nan Zhang(Huazhong University of Science and Technology), Zeyu Wang(Anhui University), Hao Zhang(Northwestern Polytechnical University), Jian Zhang(Zhujiang Hospital), Liyang Zhang(Central South University), Zhixiong Liu(Central South University), Zaoqu Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Weijie Ye(Central South University), Fangkun Liu(Central South University), Lanhua Tang(Central South University), Hui Cao(Universidade de Vigo), Zaoqu Liu(Central South University), Zhixiong Liu(Central South University), Lifu Long(Central South University)
Cited by 64
Related Papers
NF-κB in biology and targeted therapy: new insights and translational implications
|Signal Transduction and Targeted Therapy|2024|1.6k
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
PARP inhibitor resistance: the underlying mechanisms and clinical implications
|Molecular Cancer|2020|548
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
|Journal of Experimental & Clinical Cancer Research|2021|535